Pheochromocytoma: Current Approaches and Future Directions
Learning Objectives After completing this course, the reader should be able to: Use current practice methods in the diagnosis of pheochromocytomas. Employ current practice methods in the treatment of pheochromocytomas. Evaluate the current molecular research that contributes to the treatment of pheo...
Saved in:
Published in: | The oncologist (Dayton, Ohio) Vol. 13; no. 7; pp. 779 - 793 |
---|---|
Main Authors: | , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Durham, NC, USA
AlphaMed Press
01-07-2008
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Learning Objectives
After completing this course, the reader should be able to:
Use current practice methods in the diagnosis of pheochromocytomas.
Employ current practice methods in the treatment of pheochromocytomas.
Evaluate the current molecular research that contributes to the treatment of pheochromocytomas.
This article is available for continuing medical education credit at CME.TheOncologist.com
Pheochromocytomas are rare catecholamine‐secreting tumors that arise from chromaffin tissue within the adrenal medulla and extra‐adrenal sites. Because of the excess secretion of hormones, these tumors often cause debilitating symptoms and a poor quality of life. While medical management plays a significant role in the treatment of pheochromocytoma patients, surgical excision remains the only cure. Improved medical management and surgical techniques and an increased understanding of hereditary disease have improved the outcome of pheochromocytoma patients with benign disease; however, the outcome of patients with malignant disease remains poor. In this review, we discuss the presentation, diagnosis, management, and future directions in the management of this disease.
This review summarizes the presentation, diagnosis, surgical intervention, postoperative management, and future directions in the treatment of benign and malignant pheochromocytomas. |
---|---|
Bibliography: | H.C. has received honoraria from Novartis. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors, planners, independent peer reviewers, or staff managers. Disclosure Co‐first authors. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ISSN: | 1083-7159 1549-490X |
DOI: | 10.1634/theoncologist.2008-0043 |